MDM2 negatively regulates the human telomerase RNA gene promoter by Zhao, J. et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
MDM2 negatively regulates the human telomerase RNA gene 
promoter
Jiangqin Zhao1, Alan Bilsland2, Katrina Jackson2 and W Nicol Keith*2
Address: 1Department of Cell Physiology and Pharmacology, Faculty of Medicine and Biological Sciences, University of Leicester, Leicester, LE1 
9HN, UK and 2Centre for Oncology & Applied Pharmacology, University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, 
Switchback Rd, Glasgow G61 1BD, UK
Email: Jiangqin Zhao - jz27@le.ac.uk; Alan Bilsland - a.bilsland@beatson.gla.ac.uk; Katrina Jackson - k.jackson@beatson.gla.ac.uk; W 
Nicol Keith* - n.keith@beatson.gla.ac.uk
* Corresponding author    
Abstract
Background: We have previously demonstrated that NF-Y and Sp1 interact with the human
telomerase RNA (hTR) promoter and play a central role in its regulation. We have also shown that
pRB activates the hTR promoter, but the mechanism of pRb directed activation is unknown. It has
recently been reported that pRB induces Sp1 activity by relieving inhibition mediated by mdm2. The
aim was to investigate possible roles for mdm2 in hTR promoter regulation.
Methods: Chromatin immunoprecipitation was used to determine binding of mdm2 to the hTR
promoter. Transfection and luciferase assays were used to investigate mdm2 repression of the
promoter activity and interaction with known transcriptional modulators.
Results: Here we show using chromatin immunoprecipitation that mdm2 specifically binds the
hTR promoter in vivo. Transient co-transfection experiments using an hTR promoter luciferase
reporter construct show that hTR promoter activity is inhibited by over-expression of mdm2 in
5637 bladder carcinoma cells (p53 and pRB negative, low mdm2). Titration of mdm2 was able to
antagonise activation of hTR promoter activity mediated by pRB or Sp1 over-expression, although
in the presence of pRB, mdm2 could not repress promoter activity below basal levels. Using an Sp1
binding site mutation construct we showed that mdm2 repression did not absolutely require Sp1
binding sites in the hTR promoter, suggesting the possibility of pRB/Sp1 independent mechanisms
of repression. Finally, we show that NF-Y mediated transactivation of the hTR promoter was also
suppressed by mdm2 in a dose-dependent manner.
Conclusions: These studies suggest that mdm2 may inhibit the hTR promoter by multiple
mechanisms. Mdm2 may directly repress activation by both pRB and Sp1, or activation by NF-Y.
Furthermore, the ability of mdm2 to interact and interfere with components of the general
transcription machinery might partly explain the general repressive effect seen here. Elucidation of
new regulators affecting hTR basal promoter activity in cancer cells provides a basis for future
studies aimed at improving our understanding of the differential hTR expression between normal
and cancer cells.
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Telomerase is a ribonucleoprotein complex that consists
of an essential RNA molecule, hTR, with a template
domain for telomeric DNA synthesis and of a catalytic
protein, hTERT, with reverse transcriptase activity. Func-
tional telomerase is minimally composed of both hTR
and hTERT [1,2]. The transcriptional control of these two
genes is a major step in the regulation of telomerase
expression in human cells, with high expression of both
genes detected in cancer cells relative to normal cells [3-6].
Several groups have recently reported transcriptionally
targeted cancer gene therapy strategies based on the differ-
ential activities of hTR and hTERT promoters between
normal and cancer cells [7-11]. Thus, investigation of the
activating and repressive mechanisms of telomerase gene
transcription has become an area of intense interest in
cancer research.
The molecular regulation of hTR gene transcription in
cancer cells remains poorly understood. The previously
identified core promoter region in the hTR gene has sev-
eral features utilised by the basal RNA PolII transcription
machinery, including one CCAAT-box and four Sp1 sites
termed Sp1.1-Sp1.4. The activity of the hTR promoter is
controlled by NF-Y, Sp1 and Sp3 in bladder cancer cells in
vitro and we have recently shown that an Sp1 site muta-
tion in the hTR promoter detected in a blood sample
taken from a paroxysmal nocturnal haemoglobinuria
(PNH) patient can alter core promoter activity in vitro,
raising the possibility that mutation might affect hTR gene
transcription in hematopoietic cells in vivo [12-14]. Sev-
eral other known transcriptional regulators, including the
retinoblastoma protein pRB, are able to affect hTR tran-
scription in the experimental setting of over-expression
[12,13].
The mechanism whereby pRB activates hTR remains
unknown though pRB is not known to interact directly in
a specific fashion with DNA, relying instead on recruit-
ment to genes through interaction with other transcrip-
tional regulators including Sp1 and mdm2. The recent
finding that pRB induces Sp1 activity by binding to mdm2
resulting in the physical release of Sp1 from mdm2 and
enhancement of its binding to consensus sequence
implies that mdm2 might inhibit promoters such as hTR
that are positively regulated by pRb and Sp1 [15]. In this
study, we investigated regulation of hTR reporter con-
structs by Sp1, pRb, NF-Y and mdm2 and performed chro-
matin immunoprecipitation (ChIP) assays to determine
whether mdm2 plays a role in hTR regulation in the p53
and pRb negative bladder cancer cell line 5637 which also
expresses relatively low levels of mdm2 [16]. We found
that mdm2 interacts with the hTR promoter in vivo and
that mdm2 expression can down-regulate hTR promoter
activity and suppress pRb, Sp1 and NF-Y-mediated trans-
activation. Sp1 sites within the hTR core promoter were
not absolutely required for this negative effect. These stud-
ies demonstrate that hTR transcription is dominantly
repressed by mdm2 through functional, and possibly
physical, interactions with the hTR promoter complex.
Methods
Materials and cell culture
Antibodies to Sp1, TFIIB and mdm2 were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Rabbit
polyclonal antibodies directed against NF-YA, B and C
were obtained from R. Mantovani (University of Milan,
Milan, Italy). The 5637 cell line, originally established
from the primary bladder carcinoma of a 68-year-old man
in 1974, was purchased from DSMZ (No: ACC 35). 5637
cells were maintained at 37°C in 5% CO2 in 1640
medium supplemented with 10% foetal bovine serum,
penicillin, and streptomycin.
Plasmid construction and site-directed mutagenesis
Construction of the promoter fragment hProm867 and
subcloning as an Xho I/Hind III fragment in the luciferase
reporter pGL3-Basic (Promega, Madison, WI) was previ-
ously reported [17]. The reporter contains an 867 bp frag-
ment of the hTR promoter. For generation of the Sp1 site
mutation construct a two step cloning strategy was used to
prevent unexpected mutations in luciferase reporter vec-
tors; (i) an hTR 176 bp fragment (2923 wt, spanning from
-107 to +69 bp) was cloned into the Xho I/Hind III sites
in pCR-Script™ plasmid vector (Stratagene, La, Jolla CA),
which was used as template for PCR mutagenesis using a
QuikChange™ site-directed mutagenesis kit (Stratagene,
La, Jolla CA) following the manufacturer's instructions.
(ii) All mutation fragments were reconstructed into the
Xho I/Hind III sites of pGL3-basic vectors and verified by
DNA sequencing. The multiple-site mutation construct
was generated in several separate PCR reactions as previ-
ously described [12].
Transfection and dual-luciferase reporter assay
The hTR promoter plasmids containing firefly luciferase
reporters were cotransfected into tumour cells with an
internal Renilla luciferase control, pRL-SV40 (Promega)
using Superfect Transfection Reagent (Qiagen) as previ-
ously described [12,13]. 5637 cells were cotransfected
with 0.5 µg of expression vectors encoding wild-type NF-
YA, B and C (kindly donated by Dr R. Mantovani [18]),
titrations of Sp1, pRb and mdm2, 3 µg of the plasmids
containing the luciferase reporter gene and 0.5 µg of pRL-
SV40 plasmid for control of transfection efficiency. The
total amount of DNA was kept constant at 10 µg with
Salmon sperm DNA. The activity of both firefly and
Renilla luciferase was determined 48 h later using the Dual
Luciferase Assay kit (Promega). A minimum of three inde-
pendent transfections were performed in duplicate andPage 2 of 9
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as described elsewhere [12,13].
Chromatin immunoprecipitation assays
Formaldehyde cross-linking and chromatin immunopre-
cipitation were performed as described previously [19]. In
brief, 5637 cell cultures were treated with formaldehyde
for 10 min followed by the addition of glycine to a final
concentration of 0.125 M. Cells were then washed twice
with cold PBS and were resuspended in lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCI, pH 8.1) with a pro-
teinase inhibitor. After brief sonication to fragment the
DNA with an average fragment size of 500 bp, the DNA
fragments crosslinked to the proteins were enriched by
immunoprecipitation with specific antibodies. A "No-Ab"
sample was included as a negative control for the immu-
noprecipitation step. After reversal of the crosslinks and
DNA purification, the extent of enrichment was moni-
tored by PCR amplification of promoters using forward
and reverse primers to the hTR (5'-TACGCCCTTCTCAGT-
TAGGGTTAG-3' and 5'-AGCCCGCCCGAGAGAGTGAC-
3') gene promoter fragments [Zhao, 2003 #9] and to the
GAPDH coding region as a negative control (5'-TGAAG-
GTCGGAGTCAACGGATTTGGT-3' and 5'-CATGT-
GGGCCATGAGGTCCACCAC-3'). The PCR product was
separated by agarose gel electrophoresis. The input
mdm2 interacts with the hTR core promoter in vivoFigure 1
mdm2 interacts with the hTR core promoter in vivo. Formaldehyde cross-linked chromatin was prepared from 5637 
cells and immunoprecipitated with antibodies to Sp1 (lane 4), TFIIB (lane 5) and mdm2 (lane 6), or in the absence of antibody 
(lane 3). PCR detection of DNA sequences immunoprecipitated with each antibody is shown in these lanes. PCR was per-
formed with specific primers for the hTR promoter and for the GAPDH coding region as a negative control. A sample repre-
sentative of the total input chromatin (input DNA lanes 1 and 2) was included in the PCR analysis. Lanes 7 and 8 show PCR 
positive and negative controls. Chromatin immunoprecipitation experiments were repeated three times and PCR analysis of 
individual experiments was also performed at least twice.Page 3 of 9
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the point at which the cross-links were reversed. All chro-
matin immunoprecipitation experiments were repeated
three times and PCR analysis of individual experiments
was also performed at least twice.
Results
Mdm2 interacts with hTR core promoter in vivo
Regulation of hTR promoter activity by pRb and Sp1 sug-
gests that mdm2 might also play a role in hTR promoter
regulation. To investigate whether mdm2 protein targets
the hTR promoter in vivo , we performed chromatin
immunoprecipitation experiments using antibodies to
Sp1, TFIIB and mdm2. The presence of the hTR promoter
in chromatin immunoprecipitates was detected by semi-
quantitative PCR. Antibodies to Sp1 and TFIIB, both of
which have previously been detected at the hTR promoter
in chromatin immunoprecipitation, and to mdm2 all pre-
cipitated the hTR core promoter DNA sequence but failed
to precipitate the negative control GAPDH coding
sequence from 5637 cells (Fig. 1). These results establish
that mdm2 binds the hTR core promoter in vivo.
Mdm2 represses the hTR promoter and pRb and Sp1 
mediated transactivation
To address whether mdm2 affects the activity of the hTR
promoter in vitro, a luciferase reporter carrying an 867 bp
fragment of the hTR promoter (-798/+69) was used in
transient co-transfections with a full-length mdm2 expres-
sion vector. As shown in Fig. 2, the hTR promoter was
repressed by mdm2 in a dose dependent manner. Pro-
moter activity under maximal repression by mdm2 was
42% of basal activity using 3 µg of the mdm2 expression
vector.
Mdm2 has been shown to interact with the transcription
factor Sp1 in vitro and in vivo and to inhibit transactivation
of Sp1-activated promoters [15,20]. We next tested
whether mdm2 could interfere with Sp1 and pRb medi-
ated transactivation of the hTR promoter. The 5637 cell
line expresses low levels of mdm2 and does not express
functional p53 or pRb [16]. As shown in Fig. 3A, and as
previously reported, co-transfection of 5637 cells with
Sp1 increased hTR promoter activity 2-fold relative to the
vector control. Mdm2 overexpression was able to repress
Sp1 mediated activation at all mdm2 concentrations, with
Sp1 mediated induction completely abolished in the pres-
ence of 1 µg mdm2. Even in the continued presence of
Sp1 overexpression, at high mdm2 concentrations pro-
moter activity was reduced to sub-basal levels similar to
those observed with mdm2 alone. Similarly, pRb
overexpression led to a 3.75-fold induction of promoter
activity that could be repressed in a dose dependent man-
ner by titration of mdm2 (figure 3B). Interestingly
though, at the plasmid concentrations used, even the
highest concentration of mdm2 did not completely
inhibit induction by pRb. Promoter activity was still
induced by 1.7-fold in the presence of both pRb and 3 µg
mdm2, rather than repressed to the sub-basal levels
observed with Sp1/mdm2 co-expression.
To investigate whether this repression of the hTR pro-
moter by mdm2 was entirely dependent on Sp1, we trans-
fected a core promoter construct harboring functional
mutations in all Sp1 binding sites. It should be noted the
construct used here contains a shorter promoter fragment
than that used throughout. Our previous study showed
mdm2 represses hTR promoter activityFigure 2
mdm2 represses hTR promoter activity. The pRB/p53 
negative cell line 5637 were co-transfected with 1.5 µg of the 
pLh2023(-796/+69) construct and increasing amounts of 
mdm2 expression vector (from 0.5 to 4.0 µg). Total input 
DNA amount for transfection was adjusted with Salmon 
Sperm DNA to ensure a constant amount in all transfections. 
After 48 hour of culture, cells were harvested, and cell 
lysates were assayed for firefly and Renilla luciferase activity. 
The data is expressed as fold induction of luciferase activity 
relative to the promoter alone and data presented are the 
mean of three independent experiments performed in 
duplicate.Page 4 of 9
(page number not for citation purposes)
BMC Cancer 2005, 5:6 http://www.biomedcentral.com/1471-2407/5/6Mdm2 represses pRb and Sp1 mediated hTR promoter transactivation a) mdm2 suppresses Sp1 activation of hTR promoter activityFigure 3
Mdm2 represses pRb and Sp1 mediated hTR promoter transactivation a) mdm2 suppresses Sp1 activation of 
hTR promoter activity. 5637 cells were co-transfected with 1.5 µg of the pLh2023(-796/+69) construct, 2.0 µg of the 
expression vector for either Sp1 and a titration of mdm2. Total input DNA amount for transfection was adjusted with Salmon 
Sperm DNA to ensure a constant amount in all transfections. After 48 hour of culture, cells were harvested, and the cell 
lysates assayed for firefly and Renilla luciferase activity. The data is expressed as fold induction of luciferase activity relative to 
the promoter alone and data are the mean of three independent experiments performed in duplicate. b) mdm2 suppresses 
pRB activation of hTR promoter activity 5637 cells were co-transfected with 1.5 µg of the pLh2023(-796/+69) construct, 
2.0 µg of the expression vector for either pRb and a titration of mdm2. Total input DNA amount for transfection was adjusted 
with Salmon Sperm DNA to ensure a constant amount in all transfections. After 48 hour of culture, cells were harvested, and 
the cell lysates assayed for firefly and Renilla luciferase activity. The data is expressed as fold induction of luciferase activity rel-
ative to the promoter alone and data are the mean of three independent experiments performed in duplicate. c) Sp1 sites in 
the hTR promoter are not essential for repression by mdm2 5637 cells were co-transfected with 3.0 µg of the 2923 
wild type or 2923 mSp1(4) mutant constructs [13], together with mdm2. After 48 hour of culture, cells were harvested, and 
the cell lysate were assayed for firefly and Renilla luciferase activity. The data is expressed as fold induction of luciferase activity 
relative to the promoter alone and the means of the three independent experiments performed in duplicate.Page 5 of 9
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the activity of this hTR core promoter or its ability to be
transactivated by NF-Y, but disrupts Sp1 binding and acti-
vation [13]. As shown in figure 3C, mdm2 was also able
to repress this mutant, indicating that Sp1 is not essential
for mdm2 mediated repression of the hTR promoter in
vitro. Furthermore, gel shift analysis using a probe corre-
sponding to the Sp1.3 site did not produce an mdm2 spe-
cific supershift, suggesting that mdm2 may not directly
bind the hTR promoter DNA (data not shown).
Mdm2 interferes with NF-Y-dependent activation of hTR 
promoter
Since mdm2 can influence the basal activity of the hTR
reporter without targeting its Sp1 binding sites, it is likely
that at least part of the repressive effect is directed through
another pathway. One alternative mechanism by which
mdm2 could regulate the construct is through interfering
with the NF-Y-CCAAT-box complex. Therefore, we next
tested whether mdm2 could repress NF-Y function. As
shown in Fig. 4, the hTR promoter is strongly stimulated
(more than 5-fold induction) by co-transfection of expres-
sion vectors encoding the three NF-Y subunits, NF-YA, B
and C. Titration of mdm2 again resulted in dose-depend-
ent inhibition of promoter induction, reducing NF-Y
mediated activation to 1.4-fold relative to basal levels at
the highest mdm2 concentration. Thus, forced expression
of mdm2 also attenuates NF-Y-activated transcription.
This finding suggests that in addition to Sp1 dependent
effects, down-regulation of hTR promoter activity by
mdm2 may also be mediated partly by a mechanism
involving inhibition of NF-Y-activated transcription.
Discussion
The retinoblastoma gene product pRb acts as a positive
regulator of hTR promoter activity by an unknown mech-
anism while Sp1 and NF-Y activate the hTR promoter by
directly binding to DNA. Recent studies have suggested
that pRb can mediate stimulatory effects at Sp1 stimulated
promoters by liberating Sp1 from negative regulation by
mdm2 [15,21-23]. Mdm2 regulates the activities of both
p53 and pRB, and physically interacts with Sp1 to repress
transcription [24-26]. Conversely, pRB interaction with
mdm2 displaces Sp1 and restores Sp1 DNA binding and
transactivation activity. Additionally, mdm2 protein acti-
vates the p53 pathway under stress conditions and also
represses transcription directly by interaction with ele-
ments of the basal transcription machinery and their
binding sites [27,28].
In this study, we used the p53 and pRb negative bladder
cancer cell line 5637 to provide evidence that mdm2
interacts with the hTR core promoter in vivo (figure 1) and
serves as a negative regulator of the hTR gene promoter in
vitro (figure 2). Mdm2 opposed Sp1 and pRb directed
transactivation of the hTR promoter, suggesting a plausi-
ble mechanism whereby transfected pRb may elicit its
effects by opposing the action of mdm2 (figure 3). The
reciprocal scenario in which mdm2 might oppose pRB
cannot explain the negative effect of transfected mdm2
alone since the cells used here lack functional pRB. Rather,
other mechanisms, probably including direct inhibition
of Sp1 must be involved.
Mdm2 can bind directly to Sp1 and inhibit its DNA bind-
ing and can also bind to Sp1 sites at some promoters such
as that of p65 [27]. Mdm2 suppressed Sp1 mediated
transactivation in this study, but also had a more general
repressive effect that cannot have been entirely dependent
on inhibition of Sp1 since an hTR core promoter construct
Mdm2 inhibits NF-Y mediated hTR transactivationFigure 4
Mdm2 inhibits NF-Y mediated hTR transactivation. 
5637 cells were co-transfected with 1.5 µg of the pLh2023(-
796/+69) construct, 0.5 µg of expression vectors encoding 
wild-type NF-YA, B and C together with increasing amounts 
of mdm2 expression vector (from 0 to 2.5 µg). Total input 
DNA amount for transfection was adjusted with Salmon 
Sperm DNA to ensure a constant amount in all transfections. 
After 48 hour of culture, cells were harvested, and the cell 
lysate were assayed for firefly and Renilla luciferase activity. 
The data is expressed as fold induction of luciferase activity 
relative to the promoter alone and the means of the three 
independent experiments performed in duplicate.Page 6 of 9
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repressed by mdm2 (figure 3C). This clearly argues against
direct binding of mdm2 to those sites and implies the
existence of additional repressive mechanisms.
Here we demonstrated that activation of the hTR pro-
moter by over-expression of all three sub-units of NF-Y
could also be inhibited by mdm2 (figure 4). The CCAAT
box binding protein NF-Y is a ubiquitous factor with cen-
tral roles in PolII mediated transcription at numerous pro-
moters. In cooperation with accessory proteins, NF-Y
binds promoters in vivo before gene activation and "pre-
sets" the promoter architecture allowing access by other
regulatory proteins. There is also increasing evidence that
NF-Y recruits multiple components of the basal PolII
machinery [29-33]. Mdm2 and pRb have also been
reported to interact with the basal PolII transcriptional
apparatus [28,34-36]. Therefore, the possibility exists that
mdm2 also inhibits this promoter through one of these
other interactions although this remains to be tested (fig-
ure 5). Thus either an interaction with the basal transcrip-
tional machinery or specific transcription factors may
regulate hTR promoter activity.
Conclusions
In conclusion, the hTR promoter is dominantly sup-
pressed by mdm2. Mdm2 may utilise more than one
mechanism to attenuate hTR promoter activity (Fig. 5).
Mdm2 may directly repress activation by both pRB and
Sp1, or activation by NF-Y. Furthermore, the ability of
mdm2 to interact and interfere with components of the
general transcription machinery might partly explain the
general repressive effect seen here. Elucidation of new reg-
ulators affecting hTR basal promoter activity in cancer
cells provides a basis for future studies aimed at improv-
ing our understanding of the differential hTR expression
between normal and cancer cells. This will be essential for
a thorough understanding of the regulation of telomerase
Multiple mechanisms of the transcriptional repression of the hTR gene by mdm2Figure 5
Multiple mechanisms of the transcriptional repression of the hTR gene by mdm2. Schematically shown are various 
mechanisms by which mdm2 might act on the hTR core promoter. The hTR core promoter elements include Sp1 sites (recog-
nised by Sp1 family factors) and a CCAAT-box (recognized by NF-YA, B and C). NF-Y may facilitate the access of upstream 
activators (such as Sp1) to their cognate enhancer/promoter sequences, recruit TAFs components of TFIID [33] and serve to 
instigate the formation of a pre-initiation complex of general transcription factors and Pol II. Co-regulators such as pRB/mdm2 
for modulation of signals between transcription factors and the core transcriptional machinery might act through the hTR core 
promoter directly or indirectly.Page 7 of 9
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therapies.
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